NASDAQ:IBRX
ImmunityBio (IBRX)
Financials 
Technical Analysis 
Jul 2, 2026, 12:00 amThis summary was created by AI, based on 2 opinions in the last 12 months.
ImmunityBio, Inc. is a clinical stage immunotherapy company that is making strides in developing innovative therapies aimed at combating cancers and infectious diseases. In its recent quarterly report, the company reported a loss of -0.07 USD per share, which was better than analysts' expectations of -0.11 USD. Revenue for the quarter also exceeded estimates, coming in at 32.06 million USD against the expected 31.88 million USD. Looking ahead, analysts forecast a slight improvement in earnings per share to -0.09 USD and an increase in revenue to 37.88 million USD for the next quarter. Notably, social media mentions surrounding the company have surged, indicating heightened interest and engagement from the public, potentially signaling positive market sentiment.
;fill-opacity:1;'/%3e%3cpath%20d='M31%2018.6001V30H8V18.6001L14.1334%2022.4334L19.4999%2014L24.8669%2022.4334L31%2018.6001Z'%20fill='%23EE5432'%20style='fill:%23EE5432;fill:color(display-p3%200.9340%200.3310%200.1956);fill-opacity:1;'/%3e%3c/svg%3e){kind=small}
Premium contentImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA. Social media mentions are up 31% in the past 24h.
- «
- ‹
- 1
- ›
- »
Popular Articles
Most Recent Experts
ImmunityBio (IBRX) Frequently Asked Questions
What is ImmunityBio stock symbol?
ImmunityBio is a American stock, trading under the symbol IBRX (previously IBRX-Q on Stockchase) on the NASDAQ (IBRX). It is usually referred to as NASDAQ:IBRX or IBRX
Is ImmunityBio a buy or a sell?
In the last year, 2 stock analysts issued a Buy, Sell, or Hold rating on IBRX (previously IBRX-Q on Stockchase). 2 analysts recommended to BUY and 0 analysts recommended to SELL the stock. The latest stock analyst rating is TOP PICK. Read the latest stock experts' ratings for ImmunityBio.
Is ImmunityBio a good investment or a top pick?
ImmunityBio was recommended as a Top Pick by The Weekly Buzzing Stocks by Billy Kawasaki on 2026-01-22. Read the latest stock experts ratings for ImmunityBio.
Why is ImmunityBio stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for ImmunityBio.
Is ImmunityBio worth watching?
ImmunityBio is covered by Stockchase experts and is worth watching.
What is ImmunityBio stock price?
On 2026-07-02, ImmunityBio (IBRX) stock closed at a price of $9.40.
In the last quarter, the company reported -0.07 USD per share, beating the -0.11 USD estimate by 34.66%. Revenue for the same period reached 32.06 M USD, despite the estimate of 31.88 M USD. For the next quarter, analysts expect -0.09 USD in earnings per share and 37.88 M USD in revenue. Social media mentions are up 1250% in the past 24h.